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Abstract
Background:  The EST database provides a rich resource for gene discovery and in silico
expression analysis. We report a novel computational approach to identify co-expressed genes
using EST database, and its application to IL-8.
Results:  IL-8 is represented in 53 dbEST cDNA libraries. We calculated the frequency of
occurrence of all the genes represented in these cDNA libraries, and ranked the candidates based
on a Z-score. Additional analysis suggests that most IL-8 related genes are differentially expressed
between non-tumor and tumor tissues. To focus on IL-8's function in tumor tissues, we further
analyzed and ranked the genes in 16 IL-8 related tumor libraries.
Conclusions: This method generated a reference database for genes co-expressed with IL-8 and
could facilitate further characterization of functional association among genes.
Background
Chemokines are a large superfamily of small, structurally-
related peptides originally discovered as neutrophil at-
tractants. Interleukin-8 (IL-8) is a potent member of the
supergene family of CXC chemokines with ELR motif
(ELR+). ELR+ CXC chemokines are potent angiogenic fac-
tors, whereas ELR- CXC chemokines are potent angiostatic
factors. Studies have shown that these angiogenesis-relat-
ed activities are correlated with tumorigenesis in many tu-
mor types and are distinct from their ability to recruit
neutrophils [1,2].
Interleukin-8 (IL-8) is inducible in a wide range of cells in-
cluding lymphocytes, monocytes, endothelial cells, fi-
broblasts, hepatocytes, and keratinocytes [3–5]. IL-8 is
also found to be constitutively expressed in several tumor
tissues including bronchogenic carcinoma, non-small cell
lung cancer, colorectal carcinoma, breast cancer, melano-
ma, prostate cancer, gastric carcinoma, and ovarian can-
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cer. While IL-8 has been implicated in growth-
potentiation [6], angiogenesis [7], metastasis [3,8], and
tumorigenesis [3,6] of various tumors, its specific role re-
mains unclear. Several observations support the assertion
that a complex interaction between IL-8 and several other
growth factors, cytokines, or other proteins is responsible
for these tumor-related events [5,9–13]. Growth regulated
protein alpha (GRO-), beta (GRO-), and ENA-78 have
been reported to be co-induced with IL-8 in A549 cells
stimulated with two proinflammatory cytokines, IL-1
and TNF- [14]. This result is consistent with the presence
of nuclear factor kappa B (NF-B) consensus binding sites
in the promoter regions of all three genes [4,15]. In addi-
tion, GRO- and - are also members of the ELR+ CXC cy-
tokine family that are reported to be important mediators
of tumorigenesis through their angiogenic properties
[2,16]. They both share one of the IL-8 receptors, CXCR2,
which has been postulated to regulate the ELR+ CXC
chemokine-mediated angiogenesis and resulting-tumori-
genesis [1]. These observations suggest that GRO- and -
may exhibit expression profiles similar to IL-8. Coordinat-
ed expression of these and other factors with IL-8 in cer-
tain tumor tissues suggests that they may be functionally
associated with IL-8 in these tumors. In order to fully un-
derstand IL-8's role in these events, it is important to in-
vestigate these coordinately expressed genes. A systematic,
unbiased approach to identification and ranking of pro-
teins related to IL-8's expression in tumor tissues/cells
may help to define the scope of IL-8's role in tumorigenic-
ity and important related interactions with other factors.
There are over 3 million human Expressed Sequence Tag
(EST) records in GenBank (Table 1), which is still growing
rapidly. EST sequences in GenBank are derived from
cDNA libraries generated from a vast array of tissue types
including normal, disease-state, and variously treated tis-
sues. The number of EST clones is reported to be propor-
tional to the abundance of cognate transcripts in the tissue
or cell type used to make the cDNA library and thus the
EST distribution can provide a quantitative assessment of
differential expression of a gene [17]. The expanding tis-
sue diversity and EST coverage have increased the statisti-
cal power of EST-distribution based expression analysis.
An approach using EST expression data as a binary varia-
ble (present or absent in a cDNA library) has previously
identified prostate cancer-associated genes [18]. We are re-
porting here a novel in silico approach for identification of
genes whose mRNA are enriched in libraries where IL-8 is
represented. We focused on ESTs from cDNA libraries in
which IL-8 has been sequenced at least once and analyzed
the EST frequency of occurrence for all other genes in
these IL-8 related cDNA libraries. Those cDNA libraries
were further catalogued into tumor and non-tumor librar-
ies, which allowed us to identify genes whose expression
profile is closely related to that of IL-8 in tumor tissues.
Results
Genes co-expressed with IL-8
We found that IL-8 has been sequenced in 53 dbEST
cDNA libraries (Table 1 and Additional file 1). Using
these cDNA libraries (referred to as IL-8 tissue), we gener-
ated a reference database for all the genes and their expres-
sion profile relationship (measure by Z-score) with IL-8.
The complete list of genes is provided in additional file 2,
along with a distribution table based on contig size and Z-
score (Table 2). A gene could be represented by multiple
contigs which represent splice variants and sequencing er-
rors. In this database, we provide the statistics for each
contig, including the number of EST clones, cDNA librar-
ies, EST clones in IL-8 tissue, and cDNA libraries in IL-8
tissue. First we evaluated the performance of this search
using the distribution analysis results for some known
genes (Table 3). The co-expression of IL-8 with IL-6, GRO-
, and GRO- in many tissues has been well documented
[5,14,19], and those genes are identified here as IL-8 relat-
ed genes with an IL-8 Z-score >= 3. The GRO- and ENA-
Table 1: dbEST cDNA library summary. The cDNA libraries are catalogued into libraries where IL-8, GRO-, or GRO- is represented. 
Tumor libraries are cDNA libraries prepared from tumor tissues or tumor cell lines based on dbEST library annotation. See Additional 
file 1 for the detailed description of cDNA libraries where IL-8 is represented.
Total Libraries Tumor Libraries
Gene(s) ESTs Clones Libraries ESTs Clones Libraries
IL-8 329649 306888 53 173152 171521 16
GRO- 337364 349476 34 175968 174072 13
GRO- 224993 213645 27 161390 159808 12
dbEST Total 3350920 3043217 4419 896990 864427 2734BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/29
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78 [14] also show a high IL-8 Z-score, although the avail-
able EST clone number for these two genes is much small-
er. Successful identification of these genes demonstrates
the value of our in silico approach. Besides Z-score, this da-
tabase can be sorted in many different ways. For example,
we can adjust the stringency of correlation by using the
number of IL-8 cDNA libraries as a cutoff parameter.
The significance of this study lies in the generation of a
complete reference database for IL-8 co-expressed genes.
We present here a list of 36 genes with high EST clone
count (>= 100) and high Z-score (>= 3) (referred to as IL-
8 genes, I-1, I-2, ..., I-36) (Table 4) to illustrate the usage
of this reference database. A high EST clone count is used
to ensure the statistic significance of the data mining re-
sults. IL-8 tissues represent both tumor tissues/cells (IL-8-
tumor) and non-tumor tissues/cells (Table 1 and Addi-
tional file 1). To generate a tumor expression profile, the
percentage of IL-8-tumor clones versus IL-8 clones (Rtu-
mor) was calculated for the 36 IL-8 genes. The resulting
graph is shown in Figure 1. The Rtumor profile reveals a bi-
modal distribution. In the case of IL-8, tumor clones ac-
count for approximately 17% of all IL-8 clones (Rtumor =
17%). Eleven IL-8 genes exhibit a Rtumor of greater than
80%; five of these being greater than 95% (kruppel-like
factor 2 (KLF2), presenilin 1 (PS1), neural proliferation
and differentiation control protein-1 (NPDC1), GW112
and claudin-3). On the other hand, eight genes were not
found in any IL-8-tumor related library (Rtumor = 0).
For comparison with GRO- and GRO-, the ratios of IL-
8 clones, GRO- clones and GRO- clones to total
clones(Ril8, RGRO- and RGRO-) for each IL-8 gene were
analyzed. Approximately half of the IL-8 genes show sim-
ilar correlation with all three chemokines. As an example,
GW112 exhibits high correlation with IL-8, GRO- and -
 (Ril8 = 69%, RGRO- = 71%, RGRO- = 68%). On the oth-
er hand, KLF2 (Ril8 = 71%, RGRO- = 16%, RGRO- = 2%)
and PS1 (Ril8= 65%, RGRO- = 5%, RGRO- = 3%) show
Table 2: Contigs identified in IL-8 tissue and IL-8-tumor tissue. Contigs are catalogued using different Z-score and total clone cutoffs. 
Total Clone: The total number of clones from all cDNA libraries within a contig. IL-8 contigs: Contigs identified in IL-8 tissue. IL-8-tu-
mor contigs: Contigs identified in IL-8-tumor tissue. NC: no Z-score cutoff is applied.
Total Clone Cutoff Z-score Cutoff
NC 1 2 3
IL-8 Contigs 5 15222# 3130 991 352
10 14700 2662 755 274
50 8063 1010 249 98
100 3243 393 102 36
IL-8 Tumor Contigs 5 10016^ 1987 577 198
10 9776 1825 520 183
50 6677 985 281 102
100 3020 403 115 42
# See Additional file 2 for detailed list. ^See Additional file 3 for detailed list.
Table 3: EST Clone distribution for some known IL-8 related genes in the IL-8 tissue. Total Clones: The total number of clones from all 
cDNA libraries. IL-8 Clones: The number of clones from IL-8 tissue.
Gene Total Clones IL-8 Clones IL-8 Z-score
IL-6 44 24 4.1
GRO- 52 25 3.2
GRO- 46 22 3
GRO- 8 5 3.9
ENA-78 6 4 2.8BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/29
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high correlation with IL-8 and only slight association with
GRO- or GRO-.
Genes co-expressed with IL-8 in tumor tissues or cell lines
A set of tumor cDNA libraries in which IL-8 is expressed (a
subset of the IL-8 tissue cDNA libraries), was generated
and is referred to as IL-8-tumor tissue. This virtual tissue
consists of 16 cDNA libraries (171,521 cDNA clones) (Ta-
ble 1 and Additional file 1). An IL-8-tumor gene database
was established based on these libraries. The complete list
of genes is provided in additional file 3, along with a dis-
tribution table based on contig size and Z-score (Table 2).
We present here 42 candidate genes with relatively high
levels of expression in IL-8-tumor tissue (EST clone count
>= 100 and IL-8-tumor Z-score >= 3) (referred to as IL-8-
tumor genes, IT-1, IT-2, ..., IT-42) (Table 5). To determine
whether these genes are specifically related to IL-8-tumor
tissue or whether they are also commonly found in tu-
mors lacking IL-8 expression, the ratio between IL-8-tu-
mor clones and general tumor clones (Ril8tumor) was
plotted for IL-8-tumor genes (Figure 2). The Ril8tumor for
all IL-8 tumor genes are greater than 38%, which is much
higher than the expected background ratio between IL-8-
tumor clones (171521, Table 1) and general tumor clones
(864428, Table 1). A few of these genes are highly specific
to IL-8-tumor tissues. Most notably GW 112, PS1, and
KLF2 show Ril8tumor values of 86%, 81% and 76% respec-
tively.
Discussion
The vast amount of available EST data allows expression
analysis based solely on computational methods. It is pos-
Figure 1
Distribution of IL-8 related genes in tumor cDNA libraries. The percentage ratio of IL-8-tumor clones/IL-8 clones
(Rtumor) was calculated for each IL-8 related gene. The result is plotted here with gene id on the x-axis and Rtumor on the y-
axis. A bimodal distribution is obtained where most genes are either highly associated (>80%) with tumor libraries or they
show very little association (<10%) with tumor libraries. Five genes have an Rtumor value of >95%: KLF2 (99.5%), PS1 (98.9%),
NPDC1 (97.9%), GW112 protein (97.4%), and claudin-3 (96.6%).
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sible to construct a "virtual tissue" based on the expres-
sion pattern of a particular gene or group of genes (e.g.
tumor marker genes). It is also possible to group genes by
tissue type through combining genes from the same
source tissue (e.g. tumor, brain, etc.). In this study we have
generated "virtual tissues" based on (a) expression of IL-8
in all tissues and (b) expression of IL-8 in tumor tissues.
Next we generated lists of genes that are most highly co-
expressed with IL-8 in these two virtual tissues. Since the
method is not limited to genes previously correlated with
IL-8 expression nor to known genes, we have the opportu-
nity to identify previously overlooked correlations with
known or novel genes. In addition, the relative strength of
the correlations is measured by a Z-score based on the
number of clones representing IL-8 or IL-8-tumor tissue
compared with the total number of clones. Assuming that
co-expression is related to function, these Z-scores provide
a basis for ranking genes according to potential involve-
ment in IL-8's function. This reference database for genes
co-expressed with IL-8 can be cross-referenced with other
Table 4: IL-8 related genes (IL-8 Z-score >= 3 and EST clone >= 100). Total Clones: The total number of clones from all cDNA libraries. 
IL-8 Clones: The number of clones from IL-8 tissue. These genes are sorted by the ratio of IL-8 clones/total clones and given a gene id 
(I-1, I-2, ..., I-36).
Gene ID Definition#
IL-8 Clones/Total Clones (%)
I-1 IL-8 (SW:P10145) 100
I-2 serum albumin (SW:P02768) 88
I-3 fibrinogen gamma-a chain (SW:P02679) 87
I-4 aldolase B (P05062) 87
I-5 fibrinogen gamma-B chain (GI:71828) 74
I-6 kruppel-like factor 2 (SW:Q9Y5W3) 71
I-7 GW112 protein (GI:11544538) 69
I-8 presenilin 1 (SW:P49768) 65
I-9 selenoprotein P (GI:2654365) 58
I-10 beta-fibrinogen (GI:182430) 57
I-11 splice variant of serum albumin (GI:28592) 56
I-12 alpha-1-antitrypsin (SW:P01009) 56
I-13 complement factor B (GI:291922) 53
I-14 MSTP032(GI:13376832) 52
I-15 serotransferrin (SW:P02787) 51
I-16 splice variant of fibrinogen B beta (GI:14423575) 51
I-17 lumican (SW:P51884) 50
I-18 apolipoprotein A-I (SW:P02647) 50
I-19 splice variant of complement component C4A 
(GI:387438)
50
I-20 beta-2-microglobulin (SW:P01884) 49
I-21 claudin-3 (SW:O15551) 49
I-22 arylacetamide deacetylace (SW:P22760) 48
I-23 osteoinductive factor (SW:P20774) 48
I-24 hypothetical protein (GI:6807713) 47
I-25 tumor-associated calcium signal transducer 1 
(GI:182906)
47
I-26 transgelin 2 (GI:434763) 46
I-27 complement component C4A (GI:443671) 45
I-28 secreted apoptosis related protein 1 (GI:2415415) 45
I-29 thymosin beta-4 precursor(GI:2143995) 45
I-30 secretory granule proteoglycan core protein 
(SW:P10124)
44
I-31 ceruloplasmin (SW:P00450) 44
I-32 nonspecific crossreacting antigen (GI:88276) 44
I-33 plasminogen (SW:P00747) 41
I-34 biglycan (GI:13279002) 41
I-35 hypothetical protein (GI:6807932) 40
I-36 neural proliferation differentiation and control 
protein-1 (SW:Q9NQX5)
39
# SW: Swissprot accession, GI: GenBank Identifier.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/29
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large scale expression analyses, such as microarray experi-
ments, to help decipher the regulation network and the
functions of IL-8 and IL-8 co-expressed genes.
Among the genes most highly correlated with IL-8 in tu-
mor tissues are KLF2, PS1, VEGF, and tumor necrosis fac-
tor receptor-1 (TNFR-1), lumican (keratin sulfate
proteoglycan), claudin-3, and perlecan. Cytokines (IL-2
and IL-7) induce the expression of KLF2 in activated T
cells which correlates with their survival [20]. They suggest
that KLF2 may be involved in avoiding activation-induced
cell death. It is possible that IL-8 may also mediate similar
actions. This type of action could increase the ability of tu-
mor cells to survive under conditions where cells normal-
ly apoptose.
Lumican expression has previously been correlated with
higher tumor grade, lower estrogen levels in the tumor
and younger age of patients in human breast cancer [21].
In addition, lumican is structurally related to both bigly-
can which is among the top IL-8-tumor related genes and
the human embryonal carcinoma marker antigen TRA-1-
60 [22]. These relationships support the hypothesis that
lumican may be a tumor related protein involved with IL-
8's tumorigenic function.
PS1 was also found to be highly correlated with IL-8 in
both the entire list of tissues and specifically in tumor tis-
sues. Based on EST distribution, presenilin 2 (PS2) is less
related to IL-8-tumor libraries (Z-score = 0.3, IL-8-tumor
clone/Total Clone = 10%). In the breast tumor microarray
experiments, unlike PS1, the peak level of expression for
PS2 is not in BT-549. PS1 is a gene involved in early-onset
Figure 2
Distribution of IL-8-tumor related genes in all tumor cDNA libraries. The percentage ratio of IL-8-tumor clones/
tumor clones (Ril8tumor) was calculated for IL-8-tumor related genes. The result is plotted here with gene id on the x-axis and
Ril8tumor on the y-axis, and is ordered by decreasing Ril8tumor. Only the top half genes (21) with relatively high Ril8tumor are dis-
played. The 3 most specific genes are GW112 protein (86.2%), PS1 (81.1%), and KLF2 (76.4%).
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familial Alzheimer's disease. There is accumulating evi-
dence that mutations in PS1 accelerate neurodegeneration
and facilitate apoptosis, and some researchers [23] suggest
an association with the p53 signal transduction pathway.
It was suggested that down-regulation of PS1 by wildtype
p53 and also p21WAF-1 may be independent mechanisms
leading to apoptosis and tumor suppression [24]. Our
data correlating PS1 with IL-8-tumor related tissue also
suggest a potential anti-apoptotic role for PS1 in tumori-
genesis.
Table 5: IL-8-tumor related genes (Zscore >= 3 and EST clone >= 100). Total Clones: The total number of clones from all cDNA libraries. 
IL-8 Tumor Clones: The number of clones from IL-8-tumor tissue. These are sorted by the ratio of IL-8-tumor clones/total clones and 
given a gene id (IT-1, IT-2, ..., IT-42).
Gene ID Definition#
IL-8 Tumor Clones/Total 
Clones (%)
IT-1 kruppel-like factor 2 (SW:Q9Y5W3) 70
IT-2 gw112 protein (GI:11544538) 68
IT-3 presenilin 1 (SW:P49768) 65
IT-4 claudin-3 (SW:O15551) 47
IT-5 similar to EGP314 (GI:6678752) 43
IT-6 lumican (SW:P51884) 42
IT-7 nonspecific crossreacting antigen precursor (GI:88276) 41
IT-8 complement factor B (GI:291922) 40
IT-9 transgelin 2 (SW:P37802) 40
IT-10 neural proliferation, differentiation and control protein-1 
(SW:Q9NQX5)
39
IT-11 similar to atrophin-1(GI:1732417) 38
IT-12 immunoglobulin mu chain (GI:553361) 37
IT-13 hypothetical protein (GI:6807713) 37
IT-14 hypothetical protein (GI:6807932) 36
IT-15 alpha-1 type III collagen (GI:180414) 36
IT-16 heparan sulfate proteoglycan perlecan (GI:11602963) 35
IT-17 immunoglobulin alpha-1 heavy chain constant region (GI:184749) 35
IT-18 secreted apoptosis related protein 1 (GI:2415415) 32
IT-19 anterior gradient 2 (Xenopus laevis) homolog (GI:3779197) 31
IT-20 elongation factor 1-alpha 1 (SW:P10126) 31
IT-21 signal recognition particle 9 kd protein (SW:P49458) 31
IT-22 similar to CDK5 activator-binding protein C53 (GI:10435740) 31
IT-23 alpha-2-macroglobulin (SW:P01023) 31
IT-24 beta-2-microglobulin (GI:179318) 30
IT-25 vascular endothelial growth factor (GI:3712669) 30
IT-26 unknown 30
IT-27 similar to UNC-93 (GI:4263743) 30
IT-28 human C4 complement (GI:387438) 30
IT-29 t-complex protein 1, eta subunit (SW:Q99832) 29
IT-30 plasma protease C1 inhibitor (SW:P05155) 28
IT-31 tumor necrosis factor receptor 1 (SW:P19438) 28
IT-32 DRAL gene product (GI:1160932) 28
IT-33 unknown 28
IT-34 AF-6 (GI:3452572) 28
IT-35 ubiquitin (SW:P02248) 27
IT-36 unnamed protein product (GI:7023247) 27
IT-37 45 kda calcium-binding protein (SW:Q61112) 27
IT-38 ERF-2 (GI:509778) 27
IT-39 E74-like factor 3 (GI:1754538) 26
IT-40 connective tissue growth factor (GI:984956) 26
IT-41 mouse phospholipase D3 (GI:7242181) 25
IT-42 KIAA1536 protein (GI:7959339) 25
# SW: Swissprot accession, GI: GenBank Identifier.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/29
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Vascular endothelial growth factor (VEGF), like IL-8, is a
potent mediator of angiogenesis. VEGF has been shown to
regulate angiogenesis and metastasis of bladder cancer
[25] and several recent studies have reported correlations
with IL-8 in several cell types including bladder cancer
(TCC), non-small cell lung cancer (NSCLC) [26,27], hu-
man brain microvascular endothelial cells (HBMECS)
[28] and monocytes [29]. These data collectively demon-
strate the correlation of VEGF with IL-8 in tumor tissues.
TNF- is a well-characterized, potent inducer of IL-8 tran-
scription and an anti-apoptotic agent [30–32]. Roebuck
provides a detailed analysis of IL-8 promoter structure in-
cluding a promoter recruitment mechanism which in-
volves TNF- and the cooperativity of NF-kB and NF-IL-6
binding sites [4,32]. TNF- exerts many of its effects
through TNFR-1 and TNFR-2 receptors, thus co-expres-
sion of these receptors with IL-8 might be anticipated. Our
analysis does reveal a correlation between TNFR-1 and IL-
8 expression. Using another bioinformatic approach, Ei-
delman et al. report a close relationship between IL-8 se-
cretion in cystic fibrosis cells and expression of genes from
the TNFR-1/NFkB pathway. As is the case for several other
genes found in this study, the TNFR-1/NFkB pathway is
associated with p53/p21WAF-1 tumor suppressor systems
[33–37].
Our analysis identified several interesting genes co-ex-
pressed with IL-8 in tumor tissues which have not previ-
ously been associated with IL-8. Along with lumican,
claudin-3, KLF2, PS1, VEGF and TNFR-1 mentioned
above, these include several secreted proteins (secreted
apoptosis related protein 1 and NPDC1) which are also
likely to function in coordination with IL-8; several genes
from the well-known family of complement factors (C1
esterase, human complement C4A and complement fac-
tor B); and several unknown or hypothetical genes. Inter-
estingly, several of the genes correlate with the p53/
p21WAF-1 tumor suppressor network. We expect that some
of these genes may present important therapeutic targets
at one or more levels in the network of IL-8 mediated in-
teractions related to tumorigenesis.
Like all EST-based expression analysis, there are limita-
tions for this in silico method. First, EST-based expression
analysis is not suitable for transcripts with low abundance
(no or few representative ESTs in the database), which
precludes statistical analysis. Second, EST-based expres-
sion analysis can only indicate the co-expression of genes,
but can not accurately measure the expression level. Third,
to generate a comprehensive reference database, we decid-
ed not to exclude cDNA libraries based on the sequence
depth or special manipulation (e.g. subtraction and nor-
malization). The depth of sequencing and special manip-
ulation are not consistent across cDNA libraries, which
could also influence the sensitivity of the analysis.
The computational expression analysis methods devel-
oped here are not limited to the identification of IL-8 re-
lated genes, but can also be applied to many other
proteins of interest. This method is complementary to
other large-scale expression analysis methods (e.g. micro-
array) in that it is not limited by the physical presence of
a gene on microarray, thus it offers an unique approach to
discovering potential functional links between genes
through expression profiling.
Methods
In silico expression analysis
All non-commercial software used in these studies was
written in PERL 5.0. Human EST sequence and cDNA li-
brary information were retrieved from GenBank (Release
120) and an in-house relational database model (Sybase,
SQL Server Release 11.0, CA, Sybase Inc.) was created to
mirror the public human EST database (dbEST). The EST
sequences were first binned into clusters if they share the
same 21 mer tag beginning with ATG or CTG. Next, ESTs
in each cluster were assembled into contigs using the
PHRAP sequence assembly software (Phil Green, Unpub-
lished). Based on the ESTs corresponding to IL-8 in its
cognate contig, we generated a set of cDNA libraries in
which IL-8 is represented. This set of libraries is referred to
as IL-8 tissue and can be considered as a virtual tissue con-
sisting of 53 cDNA libraries (306,888 cDNA clones) (Ta-
ble 1 and Additional file 1). We chose contigs consisting
of at least 5 EST clones and present in at least 3 IL-8 librar-
ies. The frequency of occurrence (F) and Z-score for all the
contigs in these cDNA libraries were calculated as:
where NIL8 is the number of EST clones in IL-8 tissue for a
particular contig, Ntotal is the total EST clone count in that
contig. Contigs were collected into groups based on contig
size (number of EST clones in a contig), and small contig
groups (< 1000 contigs) were merged together with neigh-
boring groups (similar in contig size) to make sure that
there were at least 1000 contigs in each group. The ration-
al for grouping contigs based on size is that the distribu-
tion pattern of F (i.e. mean and Z-score) may vary for
F
N
N
IL
total
= 8
Z-score =
− ∑ F
F
n
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contigs of different size. n is the total number of contigs in
a contig group, F is the sum of F in a contig group, and
SDV is the standard deviation of F in a contig group. As-
suming a Gaussian Distribution, the fractions of the pop-
ulation that are greater than Z-score SDV and also above
the mean are 15.87%, 2.28%, and 0.13% for Z-scores of
1, 2, and 3 respectively. Similarly, a set of tumor cDNA li-
braries (based on their GenBank Annotations) in which
IL-8 is represented was generated. This set of libraries is re-
ferred to as IL-8-tumor tissue, consisting of 16 cDNA li-
braries (171,521 cDNA clones) (Table 1 and Additional
file 1). Using the method described above, a database for
IL-8-tumor candidate genes (using IL-8-tumor tissue) was
generated and IL-8-tumor Z-scores were calculated. Data-
bases for GRO- and GRO- related genes were generated
in a similar way using the cDNA libraries where GRO- or
GRO- were represented respectively (Table 1).
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